Isabella McDonald

Isabella McDonald

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
IMIsabella McDonald
Isabella McDonald
EBElizabeth S. Blocker
Elizabeth S. Blocker
EWElizabeth A. Weyman
Elizabeth A. Weyman
NSNeil David Smith
Neil David Smith
Andrew A. DwyerAndrew A. Dwyer
Andrew A. Dwyer
Co-creating patient-facing educational materials (PEMs) can enhance person-centered care by responding to patient priorities and unmet needs. Little data exist on ‘best practices’ for co-creation. We followed the Arksey and O’Malley framework to conduct a systematic literature search of nine databases (MEDLINE, PubMed, EMBASE, CINAHL, PsycINFO, Web of Science, Cochrane Library, Joanna Briggs Institute, TRIP—April, 2022) to identify empirical studies published in English on PEM co-creation to distill ‘best practices’. Following an independent dual review of articles, data were collated into tables, and thematic analysis was employed to synthesize ‘best practices’ that were validated by a patient experienced in co-creating PEMs. Bias was not assessed, given the study heterogeneity. Of 6998 retrieved articles, 44 were included for data extraction/synthesis. Studies utilized heterogeneous methods spanning a range of health conditions/populations. Only 5/45 (11%) studies defined co-creation, 14 (32%) used a guiding framework, and 18 (41%) used validated evaluation tools. Six ‘best practices’ were identified: (1) begin with a review of the literature, (2) utilize a framework to inform the process, (3) involve clinical and patient experts from the beginning, (4) engage diverse perspectives, (5) ensure patients have the final decision, and (6) employ validated evaluation tools. This scoping review highlights the need for clear definitions and validated evaluation measures to guide and assess the co-creation process. Identified ‘best practices’ are relevant for use with diverse patient populations and health issues to enhance person-centered care.

27 August 2024 in Annals of the New York Academy of Sciences
Verified
Journal Article
Open access
Andrew A. DwyerAndrew A. Dwyer
Andrew A. Dwyer
IMIsabella McDonald
Isabella McDonald
Richard QuintonRichard Quinton
Richard Quinton
Congenital hypogonadotropic hypogonadism (CHH) is a rare reproductive disorder caused by deficient secretion or action of gonadotropin‐releasing hormone (GnRH) and is a hormonally treatable form of male infertility. Both pulsatile GnRH treatment and combined gonadotropin therapy effectively induce spermatogenesis in 75%–80% of males with CHH, albeit the ejaculate does not usually approach normal semen parameters by WHO criteria. This is in some contrast to the cumulative fertility outcomes in females with CHH on gonadotropin treatment that are indistinguishable from those of reproductively normal females. Emerging data provide insights into early life determinants of male fertility (i.e., minipuberty), and research has identified key predictors of outcomes for fertility‐inducing treatment in men with CHH. Such developments provide mounting evidence for tailoring approaches to maximize fertility potential in CHH, although there is no clear consensus to date on the optimal approach to fertility‐inducing treatment. This review provides an up‐to‐date review on the current evidence underpinning therapeutic approaches for inducing spermatogenesis in males with CHH. In the absence of evidence‐based clinical guidelines, this synthesis of current evidence provides guidance for clinicians working with males with CHH seeking fertility.

22 May 2025 in Genes
Verified
Journal Article
Open access
PDF file
SSSamantha Strasser
Samantha Strasser
IMIsabella McDonald
Isabella McDonald
MUMelissa K Uveges
Melissa K Uveges
Sharlene Hesse-BiberSharlene Hesse-Biber
Sharlene Hesse-Biber
JKJordan Keels
Jordan Keels
Andrew A. DwyerAndrew A. Dwyer
Andrew A. Dwyer
Background/Objectives: Rare diseases are predominantly genetic in etiology and characterized by a prolonged ‘diagnostic odyssey’. Advances in genetic testing (GT) have helped shorten the time to diagnosis for rare/undiagnosed conditions. We aimed to synthesize the evidence on psychosocial factors related to GT for rare diseases to inform more person-centered approaches to care. Methods: We conducted a systematic literature search in six databases using structured terms (September 2024). Retrieved articles underwent independent dual review. Data were extracted and collated in tables for analysis. Thematic analysis was used to identify promoters/barriers to GT for patients and families. Findings were validated by a patient advocate and were reported using PRISMA-ScR guidelines. Synthesized findings were mapped to the Theory of Planned Behavior to inform intervention development. Results: Of 1730 retrieved articles, 32 were included for data extraction/synthesis. Studies employed qualitative (n = 19), quantitative (n = 10), and mixed-methods (n = 3) approaches. Nearly all (29/32, 91%) were non-interventional, reporting on decision-making cognitions/processes (19/32, 59%), attitudes/preferences (15/32, 47%), psychosocial impact (6/32, 19%), and knowledge/awareness (4/32, 8%) of pre-conception/prenatal/diagnostic GT and carrier screening. Promoters included understanding GT, ending the diagnostic odyssey, actionable outcomes, personal/family history, altruism, and reproductive decision-making. Barriers included logistical (e.g., distance, cost), psychological burden, perceived lack of benefit, and discrimination/social stigma concerns. Conclusions: Some psychosocial factors related to GT for rare diseases overlap with those in literature on GT for common conditions. Identified factors represent targets for theory-informed, person-centered interventions to support high-quality GT decisions that are informed and aligned with patient/family values and preferences.

20 March 2026 in Endocrine Connections
Verified
Journal Article
Open access
Andrew A. DwyerAndrew A. Dwyer
Andrew A. Dwyer
NSNeil Smith
Neil Smith
SSSamantha Strasser
Samantha Strasser
JKJordan Keels
Jordan Keels
IMIsabella McDonald
Isabella McDonald
RLRich Le
Rich Le
Background: Patients with congenital hypogonadotropic hypogonadism (CHH) are geographically dispersed and have unmet health and informational needs. Patients often rely on the Internet to learn about CHH, find expert care, and connect with other patients. Aims: We partnered with patients to co-design a website (virtual empowerment toolkit) and conducted an online evaluation of the website. Methods: Healthcare providers, patients, and a design team engaged in an iterative ‘design thinking’ process (i.e., empathize, define, ideate, prototype, refine, and test) to co-design the website. Subsequently, patients with CHH were recruited and evaluated the site using the ‘gold standard’ Patient Education Materials Assessment Tool for Audiovisual Materials (PEMAT-A/V). Scores ≥80% on PEMAT-A/V domains are considered ‘high quality’. Content analysis was used to group qualitative feedback into salient themes. Results: Patients were involved from the outset and in all stages of the design thinking process. Iterative patient focus groups and online surveys were used to prioritize content and refine prototypes. In total, 58 participants (48.5 ± 14.4 years) completed the online evaluation. All PEMAT-A/V domains scored >88% (i.e., ‘high quality’). Participants (47/55, 86%) rated the site ‘easy to navigate’, and 52/55 (95%) would recommend it to another patient. Qualitative feedback was largely positive and expressed appreciation for the online resource. Conclusion: Partnering with patients to co-design the virtual patient empowerment toolkit produced an understandable, actionable website that was responsive to patient priorities. This work supports the utility of co-creation and co-design for empowering patients with CHH and may serve as a roadmap for other rare diseases.